Cognition Therapeutics, Inc..
CGTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics targeting age-related degenerative diseases, particularly Alzheimer's disease and other cognitive disorders. The company's lead product candidate is Elayta (...Show More
Better Health for All
20
Cognition Therapeutics' core business is the development of zervimesine (CT1812) for neurodegenerative disorders, with clinical trials showing significant positive health impacts.
1
In Phase II trials, zervimesine demonstrated up to a 129% slowing of cognitive decline in mild Alzheimer's patients and a 91% slowing in moderate Alzheimer's patients.
2
For patients with dementia with Lewy bodies (DLB), zervimesine-treated individuals scored an average of 86% better than placebo on the neuropsychiatric inventory (NPI-12) after six months.
3
The company's entire R&D budget is dedicated to this drug, with over $111 million in NIH grants supporting its studies.
4
The company's investigational drug, zervimesine, has not yet been approved by regulatory authorities, and its safety and efficacy are not fully characterized, with risks associated with its use.
5
However, the Phase II SHIMMER trial met its primary endpoint of safety and tolerability, and most treatment-related adverse events were mild or moderate.
6
Zervimesine has been generally well tolerated in clinical studies to date.
7
The company's Code of Business Conduct and Ethics, effective March 26, 2025, emphasizes the protection of confidential proprietary information, including employee medical information and patient data, but lacks specific details on health data breaches or advanced safeguards.
8
The company aims for diversity in race, gender, geography, and socioeconomic status in its Phase 3 trials.
9
The expanded access program (EAP) for zervimesine has enrolled 32 individuals with mild-to-moderate DLB since June 2025, with an expected treatment duration of twelve months.
10
The EAP also implemented a strategy to reduce patient travel by empowering local physicians for routine monitoring.
11
The START study enrolled 540 individuals aged 50 to 85 with MCI or early-stage Alzheimer’s disease, and the SHINE study recruited 153 individuals in the same age range with mild-to-moderate Alzheimer’s disease.
12
The SHIMMER study enrolled 130 patients with mild-to-moderate DLB.
13
All clinical trials are closely monitored by regulatory authorities and independent ethics committees or institutional review boards to ensure safety issues are documented.
14
The company's products are not yet commercially available, so price accessibility is currently limited to clinical trial participation.
15
Fair Money & Economic Opportunity
0
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on drug development, not a financial institution.
1
The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, services, pricing, fees, customer financial outcomes, or financial literacy initiatives are not applicable to its core business model. While the company's clinical trials aim for diversity in socioeconomic status and geography,
2
this pertains to patient enrollment, not financial inclusion or economic opportunity as defined by the rubric for financial institutions.
Fair Pay & Worker Respect
0
No specific, concrete data points were provided in the articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. While CEO compensation was mentioned, median employee compensation was not, preventing the calculation of the CEO-median pay ratio.
1
Similarly, information regarding the share of the workforce covered by a living wage, collective bargaining agreements, health insurance, or insecure contracts was not available as a quantifiable percentage.
2
Qualitative observations about employee sentiment or potential turnover were present, but no formal engagement scores, turnover rates, safety incident rates, pay equity ratios, or labor violation counts were provided that could be mapped to the rubric's quantitative thresholds.
3
Fair Trade & Ethical Sourcing
30
In 2023, 90% of research compounds were sourced from certified sustainable suppliers.
1
Honest & Fair Business
0
No specific, concrete evidence was found in the provided articles to assess Cognition Therapeutics (CGTX.US) against any of the KPIs for the 'Honest & Fair Business' ethical value.
1
could not be accessed, and did not contain relevant information for these KPIs.
2
Kind to Animals
0
The company explicitly states that it uses animal models for product testing, including testing of drug candidates to improve effectiveness and toxicity.
1
No other specific, concrete data points related to animal welfare, such as the percentage of cruelty-free certified products, the extent of non-animal testing methods employed, the volume of animals used, or any animal welfare policies, were provided in the articles.
No War, No Weapons
0
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for age-related degenerative diseases. The provided article details an expanded access program for zervimesine (CT1812) in dementia with Lewy bodies.
1
There is no evidence in the articles of any involvement in arms manufacturing, military contracts, dual-use technologies with military applications, sales to sanctioned regimes, or any other activities related to war or weapons.
2
Planet-Friendly Business
-10
In 2023, the company reported total carbon emissions of 87.4 metric tons CO2 equivalent.
1
In the same year, it achieved a 22% reduction in waste, a 35% reduction in energy consumption, and an 18% reduction in transportation emissions.
2
The company reported zero active legal proceedings, indicating no environmental compliance violations.
3
Additionally, it invested $450,000 in environmental compliance and reported 90% sustainable suppliers with 95% supplier audit compliance.
4
Respect for Cultures & Communities
0
No relevant data was found in the provided articles to assess Cognition Therapeutics, Inc. against the 'Respect for Cultures & Communities' ethical value. The articles either discussed domain name sales
1
or were inaccessible
2
, yielding no specific metrics or information pertaining to the defined KPIs.
Safe & Smart Tech
0
The provided articles lack specific, quantitative data points required to assess Cognition Therapeutics against the 'Safe & Smart Tech' KPIs. While general statements about data handling and cybersecurity risk management are present, there is no concrete evidence regarding data breach severity (e.g., number of users affected), cybersecurity investment as a percentage of revenue, specific privacy or security certifications, details on encryption implementation, or the scope and effectiveness of security training and testing.
1
Information on AI ethics, algorithmic transparency, user data control, and vulnerability management is also absent or too vague to meet the rubric's quantitative thresholds.
2
Consequently, no KPIs can be scored based on the available evidence.
Zero Waste & Sustainable Products
0
No specific, concrete data points or facts were found in the provided articles regarding CGTX.US's performance on any of the 'Zero Waste & Sustainable Products' KPIs. The articles either discuss other entities (IQVIA, MIT) or focus solely on CGTX.US's drug development pipeline without mentioning waste management, product recyclability, packaging sustainability, or other related environmental practices.